Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 36.98M | 35.00M | 371.21M | 436.00K | 913.08M | 543.00K |
Gross Profit | -88.65M | -75.25M | 240.96M | -109.81M | 895.13M | -268.86M |
EBITDA | -455.24M | -447.31M | -202.70M | -648.99M | 391.48M | -345.25M |
Net Income | -385.66M | -366.25M | -153.61M | -650.17M | 377.66M | -348.87M |
Balance Sheet | ||||||
Total Assets | 2.17B | 2.24B | 2.23B | 2.24B | 2.75B | 1.83B |
Cash, Cash Equivalents and Short-Term Investments | 1.86B | 1.90B | 1.69B | 1.82B | 2.38B | 1.69B |
Total Debt | 219.36M | 223.69M | 238.63M | 244.02M | 225.03M | 61.43M |
Total Liabilities | 336.94M | 309.95M | 346.77M | 367.58M | 352.42M | 163.73M |
Stockholders Equity | 1.83B | 1.93B | 1.88B | 1.88B | 2.40B | 1.66B |
Cash Flow | ||||||
Free Cash Flow | -307.86M | -144.68M | -272.35M | -532.93M | 457.27M | -256.72M |
Operating Cash Flow | -306.47M | -142.77M | -260.38M | -495.74M | 538.97M | -238.37M |
Investing Cash Flow | -202.44M | -280.48M | 374.65M | -258.65M | -1.04B | -541.17M |
Financing Cash Flow | 36.64M | 331.98M | 62.66M | 38.59M | 250.94M | 1.02B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $1.84B | 12.05 | 24.71% | ― | 20.62% | 14.08% | |
54 Neutral | $4.10B | ― | -19.71% | ― | -86.13% | -67.29% | |
52 Neutral | $1.01B | ― | -34.26% | ― | 271.44% | 26.65% | |
51 Neutral | $1.64B | ― | -70.58% | ― | 100.03% | 64.22% | |
51 Neutral | $7.44B | 0.40 | -61.90% | 2.33% | 17.14% | 1.55% | |
50 Neutral | $990.26M | ― | -57.92% | ― | -13.37% | 2.57% | |
45 Neutral | $1.69B | ― | -38.04% | ― | -82.38% | -164.76% |
On June 26, 2025, CRISPR Therapeutics AG announced updates on its in vivo cardiovascular disease programs, including new data for CTX310™, CTX320™, and CTX340™. CTX310™, targeting ANGPTL3, continues to show promising results in reducing triglycerides and low-density lipoprotein in its Phase 1 trial, with peak reductions of up to 82% and 86% respectively, without significant liver enzyme changes. CTX320™, targeting the LPA gene, is in an ongoing Phase 1 trial, with an update expected in the first half of 2026. Meanwhile, CTX340™, targeting angiotensinogen for refractory hypertension, is progressing through preclinical studies. These developments highlight CRISPR Therapeutics AG’s strategic advancements in addressing cardiovascular diseases, potentially impacting its market position and offering new treatment avenues for patients.
The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.
On June 5, 2025, CRISPR Therapeutics AG held its Annual General Meeting where shareholders approved several key proposals, including amendments to the company’s Articles of Association, financial statements for 2024, and the re-election of board members and auditors. These decisions, effective upon registration, are expected to strengthen the company’s governance and operational framework, potentially enhancing its strategic positioning in the biotechnology sector.
The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.
On May 19, 2025, CRISPR Therapeutics AG announced a collaboration agreement with Sirius Therapeutics to co-develop and commercialize siRNA technology targeting Factor XI, with an upfront consideration of $95 million. The agreement includes the development of SRSD107, a next-generation siRNA designed to inhibit coagulation factor XI, showing promising results in Phase 1 trials with potential applications in various thrombotic conditions. The collaboration aims to leverage SRSD107’s potential to reduce thrombotic events while minimizing bleeding risks, positioning it as a differentiated therapy in the market.
The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.